Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:

“Long-term follow-up has shown promising results for the combination of bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma.

I treated two patients with HLRCC-related kidney cancer, and both experienced durable partial responses to bev plus erlo.

Additionally, I prescribed this combination to a patient with metastatic FH-deficient papillary RCC, who achieved a complete response. I can strongly recommend!”

Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Journal: NEJM

Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan

Read the full article.

Bevacizumab

More posts featuring Ilya Tsimafeyeu on OncoDaily.

Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma

“Long-term follow-up has shown promising results for the combination of bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma.

I treated two patients with HLRCC-related kidney cancer, and both experienced durable partial responses to bev plus erlo.

Additionally, I prescribed this combination to a patient with metastatic FH-deficient papillary RCC, who achieved a complete response. I can strongly recommend!”